Department of Rheumatology and Clinical Immunology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, 10117 Berlin, Germany.
Deutsches Rheuma-Forschungszentrum (DRFZ), Institute of the Leibniz Association, 10117 Berlin, Germany.
Int J Mol Sci. 2022 May 2;23(9):5049. doi: 10.3390/ijms23095049.
Unspecific antibody binding takes a significant toll on researchers in the form of both the economic burden and the disappointed hopes of promising new therapeutic targets. Despite recent initiatives promoting antibody validation, a uniform approach addressing this issue has not yet been developed. Here, we demonstrate that the anti-glucocorticoid receptor (GR) antibody clone 5E4 predominantly targets two different proteins of approximately the same size, namely AMP deaminase 2 (AMPD2) and transcription intermediary factor 1-beta (TRIM28). This paper is intended to generate awareness of unspecific binding of well-established reagents and advocate the use of more rigorous verification methods to improve antibody quality in the future.
非特异性抗体结合给研究人员带来了重大的经济负担和有前途的治疗靶点的希望破灭，尽管最近有一些举措推动了抗体验证，但尚未制定出解决这一问题的统一方法。在这里，我们证明抗糖皮质激素受体 (GR) 抗体克隆 5E4 主要针对大约相同大小的两种不同蛋白质，即 AMP 脱氨酶 2 (AMPD2) 和转录中介因子 1-β (TRIM28)。本文旨在提高对现有试剂非特异性结合的认识，并提倡使用更严格的验证方法来提高未来的抗体质量。
